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Alzheimer’s disease (AD) is an incurable, progressive, neurodegenerative disorder affecting
over 5 million people in the US alone. This neurological disorder is characterized by
widespread neurodegeneration throughout the association cortex and limbic system
caused by deposition of Aβ resulting in the formation of plaques and tau resulting in the
formation of neurofibrillary tangles. Active immunization for Aβ showed promise in animal
models of AD; however, the models were unable to predict the off-target immune effects
in human patients. A few patients in the initial trial suffered cerebral meningoencephalitis.
Recently, passive immunization has shown promise in the lab with less chance of off-target
immune effects. Several trials have attempted using passive immunization for Aβ, but
again, positive end points have been elusive. The next generation of immunotherapy for
AD may involve the marriage of anti-Aβ antibodies with technology aimed at improving
transport across the blood-brain barrier (BBB). Receptor mediated transport of antibodies
may increase CNS exposure and improve the therapeutic index in the clinic.
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INTRODUCTION
Dementia and its associated pathologies are a significant health
threat affecting society today. Alzheimer’s disease (AD) is the most
common form of dementia and involves the accumulation of
intra- and extra- neuronal Aβ as well as intra-neuronal Tau. There
are currently more than 5 million AD patients in the United States
and over 35 million patients worldwide. This number is expected
to double every 20 years due to the increased aging population.
AD is the 6th leading cause of death in this country and the
only cause of death among the top 10 in the United States that
cannot be prevented, cured or even slowed. Based on mortality
data from 2000–2008, death rates have declined for most major
diseases while deaths from AD have risen 66% during the same
period (Alzheimer’s association, 2013).
AD is caused by the progressive accumulation of Aβ into
oligomers and plaques leading to synaptic loss, neuronal dysfunc-
tion and death. In addition, intra-neuronal Tau aggregates form
characteristic neurofibrillary tangles that contribute to neuronal
death. Increased immune response by astrogliosis and microglio-
sis lead to pro-inflammatory cytokine release that contributes to
neuronal cell loss (Terry et al., 1994).
Aβ is formed by the systematic processing of the APP trans-
membrane protein by proteolytic cleavage on the extracellular
side of the membrane by β-secretase at the N-terminus of Aβ and
by the γ-secretase complex at the C-terminus of Aβ to generate
Aβ38, Aβ40 and Aβ42 (Figure 1; Sisodia and St George-Hyslop,
2002). Alternatively, under physiological conditions a significant
fraction of APP is cleaved at the middle of Aβ (aa 16) by proteases
with α-secretase activity (Anderson et al., 1992; Allinson et al.,
2003), such as members of a disintegrin and metalloproteinase
(ADAM) family of enzymes (Kojro and Fahrenholz, 2005), and
under α-secretase cleavage no Aβ is generated. This cleavage event
results in the production of a neurotrophic secreted (s)APP, which
acts as a growth factor for many types of cells and promotes
neurite outgrowth in post-mitotic neurons (Gralle and Ferreira,
2007).
The formation of Aβ42 fragments over Aβ38 or Aβ40 appears
to occur as a function of genetic and/or environmental factors.
The Aβ42 fragment is considered more toxic due to its ability to
readily assemble into oligomers and higher order fibrils which
themselves present toxic products to the neuron. Aβ monomers
and oligomers can also bind to cell surface receptors promoting
signaling pathways and inducing neuronal degeneration (Patel
and Jhamandas, 2012).
Aβ42 small order oligomers may also propagate from neurons
to spread the disease (Harris et al., 2010; Nath et al., 2012).
This may explain the progression of the disease and pathological
progression of Aβ accumulation and plaque deposition beginning
in the entorhinal cortex proceeding to the hippocampus and to
cortical areas (Braak and Braak, 1991, 1996). This results in pro-
gressive memory and cognitive deficits observed in the patients
(Blennow et al., 2006).
To date therapeutic interventions for AD have been primar-
ily limited to treating symptoms without the ability to target
the underlying causes of Aβ accumulation. These treatments
include acetylcholinesterase inhibitors (donepezil, rivastigmine
and galantamine) and N-methylD-aspartic acid (NMDA) glu-
tamate receptor antagonists (memantine) (Tayeb et al., 2012).
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FIGURE 1 | Systematic processing of APP forms Aβ42, Aβ40 and Aβ38.
Locations of β-secretase, α-secretase and γ-secretase cleavage sites are
depicted. Binding sites for passive antibodies are identified as
(a)—Bapineuzumab, (b)—Gantenerumab, (c)–Crenezumab,
(d)—Solanezumab, (e)—Ponezumab.
β-secretase inhibitors have been tested clinically in an attempt
to reduce the production of Aβ. These small molecule and
peptidomimetic inhibitors have succeeded in reducing plasma
and CSF levels of Aβ; however; off-target toxicity and secondary
neurodegeneration have been observed (Vassar et al., 2014).
Immunotherapy is one method that has been advanced recently
for its ability to reduce the accumulation of Aβ and potentially
treat the underlying cause of AD.
ACTIVE IMMUNIZATION
Vaccination has been an instrument in the tool chest of the
clinician since the late 18th century when Edward Jenner first used
the related cowpox virus to immunize patients against small pox.
The basic concept of active immunization is to prime the immune
system to recognize an antigen as a foreign protein in order to
mount a response against it. The most commonly recognized
active immunization strategies are used against bacterial (e.g.,
pertussis, typhoid, meningitis), viral (e.g., influenza, hepatitis,
chicken pox) and toxin (e.g., diphtheria, tetanus) antigens.
It has only been recently that investigators have attempted to
utilize the human immune system to rid the body of potentially
harmful or toxic proteins that are endogenously produced. In this
instance, the immune system has initially been taught to ignore
the proteins as “self ” antigens. Antibody producing cells (B-
cells) enter a maturation process that includes removing all cells
that could possibly generate antibodies against proteins the body
already makes in a process called B-cell tolerance. This ensures
that the immune system will not accidentally generate antibodies
or mount an immune response against itself. Thus the clinical
intervention of inducing an immune response against Aβ (an
endogenous protein) would require breaking the self-tolerance.
In addition, it was not entirely clear that it would be possible
or even effective to elicit and immune response against a neuro-
protein such as Aβ. Two important considerations slowed the
entry into the field of vaccination of a neuronal protein: (1)
Antibody transport from the blood to the brain was known
to be limited; and (2) The brain has long been considered an
immune-protected organ in the body. The barrier between the
blood and the brain is called the blood-brain barrier (BBB) and
prevents the passage of most proteins and small molecules from
entering the brain providing a protected environment for the
neurons. Only proteins with specific receptors on the BBB are
known to actively transport to the neuronal side, and antibody
receptors are not known to be expressed on the BBB so significant
transport of antibodies could not be assumed to be a given
proposition (Hussain et al., 1999). Second, the brain had long
been considered an “immune-protected” organ precisely for the
fact that few antibodies and immune-modulatory cells transit
across the BBB. It was not known that an antibody response could
be mounted to a neuronal protein or if one could, what effect it
would have.
With these facts in mind, it was a surprise in 1999 when
Schenk et al. showed that immunization of the PDGF driven
APP (PDAPP) mouse model of AD with Aβ42 could prevent the
onset of plaque formation if performed in young mice. Immu-
nization of older mice effectively slowed the progression of plaque
formation (Schenk et al., 1999). These results were replicated in
numerous animal models suggesting that they could be translated
to the clinic (Das et al., 2001; Wilcock et al., 2001).
Translation to the clinic was expected to bring a breakthrough
in treatment of AD as the first therapeutic to directly target
the generation and accumulation of Aβ protein. Clinical trial
AN1792 used the full length Aβ42 as an active vaccine with an
adjuvant to prime the immune system. 372 patients were enrolled;
however the trial was suspended at phase IIa when four patients
came down with meningoencephalitis. Later analysis showed
that of the patients that showed an antibody response to the
Aβ antigen, several (seven patients analyzed) showed significant
clearing of hippocampal Aβ plaque and reduced plaque density as
well as reduced phosphorylated tau compared to non-treated AD
patients (Masliah et al., 2005; Serrano-Pozo et al., 2010). Follow-
up studies revealed reduced CSF Tau and improved cognitive
scores (Boche et al., 2010). Further analysis of the AN1792 trial
revealed a T-cell response to the Aβ epitope found at amino acids
25–35 so future immunization strategies have attempted to avoid
this epitope (Frenkel et al., 2001).
More recent active immunization strategies have focused on
the B-cell epitopes of the Aβ protein located at the N-terminus
of the protein while avoiding the T-cell epitopes located at the
C-terminus of the protein. These include Affitope; which is
composed of a synthetic six amino acid sequence mimic of the N-
terminus of the Aβ peptide comprising the B-cell epitope without
the C-terminus T-cell epitope (Schneeberger et al., 2009). Affitope
is currently in phase II trials.
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CAD-106 is comprised of multiple copies of amino acids Aβ1-
6 expressed from the virus Qβ. Using the bacteriophage Qβ pro-
vides a scaffold for presentation of multiple copies of the Aβ1-6
epitope to a single cell to ensure maximum activation of immune
cell response, a necessity when attempting to overcome self-
tolerance. Vaccination in mouse models of AD showed reduced
CNS Aβ load (Wiessner et al., 2011). Clinical trials show good
safety data dose tolerability with antibody production (Lemere
and Masliah, 2010; Winblad et al., 2012).
Vanutide cridificar is composed of multiple copies of Aβ1-7
fused to an inactivated diphtheria toxin. Clinical trials show good
safety and tolerability with antibody titer production, and trials
are currently in phase II (NIH, 2014a).
PASSIVE IMMUNIZATION
While active immunization followed the well worn path of vac-
cination that has proven successful in the clinic at preventing
and treating diseases that presented as foreign antigens such as
bacteria, viruses and toxins; passive immunization has shown
more success in treating diseases that present with “self antigens”.
In this instance, rather than prime the human immune system
to generate and sustain an immune response against a novel
antigen, the premise is to identify an epitope in the labora-
tory, generate antibodies ex vivo and then directly inject these
antibodies into the patient. The advantages to this approach
are directing the epitope to which the antibodies will be tar-
geted, the isotype of antibody generation, the antibody dose
delivery and interval. One disadvantage to passive immuniza-
tion is the possible requirement for continuous dosing of the
antibody.
This approach has been successful in the clinic for a number
of diseases including autoimmune disorders (Humira, Actemra),
cancer (Herceptin, Rituxan) and transplant rejection (Zenapax,
Simulect) (Waldmann, 2003). Thus the idea of transferring the
knowledge gained from the use of monoclonal antibody therapies
for human therapies to neurological disorders such as AD was a
natural extension.
Based on the results obtained in the active immunization
work, antibodies were developed against the N-terminus of the Aβ
protein for direct injection. Treatment of APPtg mouse models of
AD with the antibodies showed significant reductions in CNS Aβ
and reversed memory deficits in object recognition and Morris
water maze (Dodart et al., 2002; Kotilinek et al., 2002; Bard et al.,
2003; Buttini et al., 2005).
Again the mechanism of reduction in CNS Aβ was not clear.
One hypothesis was that systemic antibodies were binding Aβ
in the blood, drawing monomeric Aβ from the brain to the
blood thus reducing the accumulation in the brain. This has
commonly been referred to as the “sink hypothesis”. The alter-
native hypothesis concerns the direct action of the antibodies
in the central nervous system. Antibodies binding directly to
Aβ might target the protein for phagocytosis. Alternatively, anti-
body binding to Aβ could prevent Aβ aggregation or uptake by
neurons.
The promising mouse data from the passive immunization
prompted investigators to move this therapeutic approach to the
clinic. Several anti-Aβ antibodies have been tested in clinical
trials: bapineuzumab, solanezumab, gantenerumab, crenezumab,
ponezumab among others in early clinical trials (Figure 1,
Table 1).
Bapineuzumab was the first passive immunotherapy in clinical
trials for AD. The humanized antibody was developed against
Aβ1-5 and was reported to bind to both amyloid fibrils as well
as plaques. Clinical trials showed little cognitive improvement in
patients with some patients receiving the high dose experiencing
vasogenic cerebral edema (Salloway et al., 2014). These patients
did recover, however clinical endpoints only showed modest
reduction in CSF Tau and no reduction in CSF Aβ so trials were
discontinued (Blennow et al., 2012). Further analysis of the data
from the clinical trial did reveal some cognitive and functional
benefits only in a subset of patients (Tayeb et al., 2013; Salloway
et al., 2014). These patients were ApoE4 non-carriers. ApoE4 is
an allele of the ApoE gene involved in cholesterol transport that is
associated with an increased risk of AD.
Similar to bapineuzumab, solanezumab is a humanized anti-
body; however it is targeted to an internal epitope of Aβ (13–
28). In addition, the antibody showed preferential binding to
soluble Aβ but not fibrillar Aβ. Clinical trials showed increased
plasma and CSF levels of Aβ following a dose dependent admin-
istration of solanezumab to patients in contrast to the trials
with bapineuzumab. Early clinical trails showed little improve-
ment in cognition in patients with moderate AD (Doody et al.,
2014), however patients with mild AD showed a 33% reduc-
tion in a rate of decline so a phase III trial has begun to
investigate the treatment of mild AD patients with solanezumab
(NIH, 2014c). Early clinical trials have shown solanezumab has
similar efficacy in patients with or without the ApoE4 allele
(Samadi and Sultzer, 2011) in contrast to the bapineuzumab
trial.
Gantenerumab is the only fully human antibody developed.
It is targeted to Aβ1-11 and appears to bind preferentially to
amyloid plaques and not to soluble amyloid. In animal models,
treatment with gantenerumab reduces brain amyloid loads with-
out increasing plasma Aβ levels as observed with solanezumab.
The likely mode of action of this antibody appears to be binding
to small plaques and inducing a phagocytic response by microglia
(Bohrmann et al., 2012). Clinical trials in mild to moderate AD
patients treated with gantenerumab reduced brain amyloid load
by up to 30% as determined by PET scan, however two patients
in the high dose group experienced vasogenic cerebral edema
(Ostrowitzki et al., 2012).
Table 1 | Summary of the most advanced passive immunotherapies
for Alzheimer’s disease.
Antibody Source Isotype Epitope Conformation
Bapineuzumab Humanized IgG1 1–5 Fibrils/plaques
Solanezumab Humanized IgG1 13–28 Monomer
Gantenerumab Human1 IgG1 1–11 Plaques
Crenezumab Humanized IgG4 12–23 Monomer,
oligomer, fibrils
Ponezumab Humanized IgG2a 33–40 Monomer, plaques
1phage derived.
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Crenezumab is a humanized antibody targeted to Aβ with
a modified human IgG isotype IgG4 to reduce the affinity for
Fc receptor binding and reduce the risk of immune cell stim-
ulation allowing higher dosing of the antibody than previous
immunotherapies had allowed. Crenezumab appears to bind to
many forms of Aβ including monomer, oligomer and fibrillar
(Adolfsson et al., 2012). Phase I trials showed good safety data
and now crenezumab is moving into Phase II testing.
Ponezumab is another humanized IgG antibody; however
unlike other antibodies tested to date, ponezumab targets Aβ40
without targeting the full-length APP protein (Freeman et al.,
2012a,b; La Porte et al., 2012). Early clinical data pointed to good
safety profile with increased plasma Aβ40; however, little to no
improvement in cognitive impairment was observed and trials
were discontinued (Burstein et al., 2013; Landen et al., 2013).
Currently, ponezumab is being examined for the treatment of
cerebral amyloid angiopathy (CAA; NIH, 2014d).
Although many of these immunotherapeutic approaches have
failed to affect significant improvements in the mild to moderate
AD patients being treated, the exact cause of failure is not known.
Two, not exclusive, hypotheses have been promoted to explain the
lack of success: (1) poor uptake of monoclonal antibody to the
CNS across the BBB; and (2) treatment of patients too late in the
progression of AD. The first point will be addressed below. The
topic of treating late stage patients with current mild to moderate
cognitive impairment is important to take into account when
reviewing the results of these trials. It has long been thought
that during the later stages of AD, many of the neurodegen-
erative changes have occurred and reducing or eliminating Aβ
accumulation at this stage may not be enough to overcome the
deficit of neuronal functional loss. Treatment of patients earlier
in diagnosis may be able to slow or stop the progression of the
disease. The difficulty has always been in identifying patients early
in the disease.
Three new trials of passive immunotherapy will attempt to
investigate whether treatment at earlier stages of the disease can
slow or stop the progression of AD. The Dominantly Inherited
Alzheimer’s Network (DIAN) will treat a group of individuals
identified to be carriers of the dominantly inherited familial
Alzheimer’s disease (FAD) gene (Bateman et al., 2012). These
patients are highly likely to suffer from early onset AD. Treat-
ment will include solanezumab and gantenerumab in a phase
II/III trial examining CSF Aβ and PET scan end points (NIH,
2014b).
The Alzheimer’s Prevention Initiative (API) follows large
groups of families in Colombia that are known carriers of the FAD
(Reiman et al., 2011). 300 people will be treated with crenezumab
with the expectation that 2/3 will develop some form of AD in
the future (Garber, 2012). Patients will be followed for changes in
biomarkers for 5 years.
Finally, a study with the Treatment of Asymptomatic
Alzheimer’s (A4) will examine older patients that are not known
carriers of gene mutations for AD, but who show early signs of Aβ
deposits determined by PET scans with no cognitive impairment.
Patients will be treated with solanezumab to determine if early
intervention, prior to the onset of cognitive decline, can prevent
or delay AD symptoms (Carrillo et al., 2013).
FUTURE DIRECTIONS
The BBB controls the passage of substances from the blood
into the central nervous system. Thus, a major challenge for
the delivery of monoclonal antibodies following either active or
passive immunization is the transport of these large proteins to
the CNS.
Previous studies with monoclonal antibodies for the treatment
of AD have shown approximately 0.1% of injected antibodies
cross the BBB with the rest either metabolized in the liver or
excreted through the kidneys (Banks et al., 2002). This low rate
of transport may at least partially account for the low clinical
success rate of several anti-Aβ therapies. In contrast, we, and
others have shown that targeting receptors on the BBB for active
transport or transytosis of protein to the CNS from the blood can
increase the brain penetration to 2–3% of injected dose (personal
observation, (Boado et al., 2013)). This increased BBB transport
may be sufficient to move some of the current antibodies from
clinically ineffective to effective.
The receptors expressed on the endothelial cells of the BBB
function to capture proteins in the blood, endocytose the protein/
receptor complex and trancytose the complex to the neuronal side
of the cells where the protein is released. Starzyk et al. were the
first to show that targeting a receptor on the BBB could transport
a “cargo” protein to the neuronal side of the BBB (Friden et al.,
1991). An antibody developed against the transferrin receptor
expressed on the BBB was able to transport methotrexate to the
CNS. This same approach has been used to target the transport of
proteins and peptides across the BBB efficiently (Shin et al., 1995;
Boado et al., 2007).
More recently, this approach has been investigated in the
context of delivering monoclonal antibodies for passive vacci-
nation immunotherapy for AD. A bi-specific IgG developed to
target the transferrin receptor with one Fab and the β-secretase
(BACE1) with the other Fab (Figure 2A) resulted in increased
brain penetration while significantly reducing brain Aβ levels
(Couch et al., 2013). The breakthrough in these results was in the
affinity of the Fab to the transferrin receptor (Yu et al., 2011). Too
high an affinity resulted in antibody that remained bound to the
transferrin receptor on the endothelial cell following trancytosis.
This failed to provide significant levels of antibody in the brain
parenchyma and failed to generate significant penetration of the
recombinant targeting antibody. In contrast, lower affinity Fab
targeted to the transferrin receptor actually increased the concen-
tration and penetration of targeted antibody without altering BBB
levels of the transferrin receptor (Bien-Ly et al., 2014).
Similarly, a bi-functional antibody developed with a full IgG
targeted to the Aβ protein fused at the Fc region to a Fab targeted
to the transferrin receptor (Figure 2B; Niewoehner et al., 2014).
This bi-functional antibody penetrated the brain parenchyma
significantly greater than the anti-Aβ monoclonal antibody alone
and showed a significantly greater reduction in accumulated Aβ,
while given at equal molar doses.
We have also targeted receptors on the BBB for the transport
of proteins to the CNS. We utilized the low-density lipoprotein
receptor (LDLR) expressed on the endothelial cells for transport
to the CNS. In contrast to the methods listed above, we have used
the endogenous LDLR binding domain of native proteins for the
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FIGURE 2 | Targeting immunotherapies for transport across the
blood-brain barrier. (A) Bi-specific IgG antibodies targeting the
transferrin receptor (TfR) and β-secretase (BACE). (B) Bi-functional IgG
antibodies target Aβ with a single Fab fragment targeting the TfR fused
by the knobs into holes approach. (C) Single chain antibody (scFV)
targeted to Aβ expressed with a linker between the heavy and light chain
with a linker to the LDLR binding domain of Apolipoprotein B (38 amino
acids).
binding/transytosis of targeted proteins. These receptor binding
domain have been identified from Apolipoprotein B (38 amino
acids) (Spencer and Verma, 2007) and Apolipoprotein E (19
amino acids) (Spencer and Verma, 2007; Böckenhoff et al., 2014)
and can be readily fused to target proteins including antibodies.
Recently, we fused the 38 amino acid LDL-R binding domain of
ApoB to a single-chain antibody (scFV) (Figure 2C). Addition of
the LDLR binding domain significantly increased brain penetra-
tion of the scFV but also presented an unique cellular uptake and
clearance mechanism (Spencer et al., unpublished).
Although it is not clear how monoclonal antibodies are cleared
from the CNS following binding to their targeted protein, one
mechanism is thought to be through the Fc receptor expressed
on microglial cells. This could lead to cell mediated cytotoxic-
ity and release of inflammatory mediators (Reviewed in Okun
et al., 2010). We found the addition of the LDLR binding
domain of ApoB, in addition to improving BBB transport, facil-
itated neuronal and glial cell uptake through the LDLR receptor
leading to endosomal sorting complex required for transport
(ESCRT) mediated endocytosis and autophagosome degradation
thus bypassing the Fc receptor signaling cascade that could lead
to cytotoxicity (Spencer et al., unpublished). scFV antibodies
targeted to Aβ could be used with this approach to target AD
(Liu et al., 2004; Fukuchi et al., 2006; Kasturirangan et al., 2009;
Kasturirangan and Sierks, 2010).
Other approaches to targeting the brain and active trans-
port across the BBB have been identified and are actively being
investigated. These may prove to be synergistic to the field of
immunotherapy and need to be followed closely. Clearly the
techniques mentioned above show that there are novel methods
for improving the concentration and penetration of immunother-
apeutic antibodies in the CNS. This would have the benefit of
not only increasing delivery of the injected dose but also possi-
bly reducing the amount of antibody needed for injection thus
reducing drug exposure and improving the safety window.
Aβ immunotherapy for the treatment of AD continues to show
promise. After the setback from the early trials involving active
immunization of full length Aβ42, current active immunization
with N-terminus Aβ and passive immunization with monoclonal
antibodies targeted to Aβ appear to show much greater promise
with larger safety margins. Still, clinical efficacy has been difficult
to achieve with the current approaches and theories as to why that
has occurred include (1) late stage disease treatment; and (2) poor
penetration of antibody to the brain. Both of these theories are
being addressed now; the first with the trials involving treatment
of individuals prior to onset of symptoms, and the second with the
development in the lab of new strategies to improve the transport
and penetration of antibodies to the CNS. The current standard
of care for AD provides a modest transient relief of symptoms,
however targeting the source of toxicity on AD may allow for
a treatment or even cure if begun early enough in the disease
course.
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